Resverlogix

Resverlogix ROCE

The Return on Capital Employed (ROCE) of Resverlogix (RVX.TO) as of Oct 25, 2026 is 5.86 %. In the previous year, Return on Capital Employed (ROCE) was 5.63 % — a change of 4.12% (higher).

ROCE

5.86 %

YoY

4.12%

Last updated:

In 2025, Resverlogix's return on capital employed (ROCE) was 5.86 %, a 4.12% increase from the 5.63 % ROCE in the previous year.

The Resverlogix ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
0.02 USD
Jan 1, 2019
35.21 USD
Jan 1, 2020
0.04 USD
Jan 1, 2021
26.68 USD
Jan 1, 2022
21.51 USD
Jan 1, 2023
8.41 USD
Jan 1, 2024
5.63 USD
Jan 1, 2025
5.86 USD
The Resverlogix ROCE history
YEARROCEYoY
5.86 %+4.12%
5.63 %-33.09%
8.41 %-60.89%
21.51 %-19.39%
26.68 %+72,955.19%
0.04 %-99.90%
35.21 %+188,720.78%
0.02 %-99.96%
49.61 %+47.58%
33.62 %-5.19%
35.46 %+209.06%
11.47 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Resverlogix Stock analysis

What does Resverlogix do? Resverlogix Corp is a biopharmaceutical company based in Canada that specializes in the research and development of innovative therapies for cardiovascular diseases. It was founded in 2001 by Dr. Donald J. McCaffrey and has been listed on the Toronto Stock Exchange since 2006. The company focuses on the development of synthetic molecules with the same potential as Resveratrol, a natural compound found in red grapes and wine, for the treatment of cardiovascular diseases. Resverlogix Corp follows an innovative business model that involves identifying disease-causing factors and developing targeted molecules to influence them, with the goal of developing effective therapies for patients with cardiovascular diseases. The company specializes in the development of therapeutic agents for atherosclerosis and diabetic nephropathy, and currently has two main products in clinical development: Apabetalone for the treatment of atherosclerosis and BAC25 for diabetic nephropathy. Apabetalone acts directly on the genome of cells and influences the gene expression of proteins relevant to the development of atherosclerosis, while BAC25 targets glucose and lipid metabolism in the kidney to slow down or prevent the development of diabetic nephropathy. Overall, Resverlogix Corp is a biopharmaceutical company focused on innovative therapies for cardiovascular diseases, with a business model based on identifying disease-causing factors and developing synthetic molecules to target them. Resverlogix is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Resverlogix's Return on Capital Employed (ROCE)

Resverlogix's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Resverlogix's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Resverlogix's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Resverlogix’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Resverlogix stock

Return on Capital Employed (ROCE) of Resverlogix is 5.86 % in 2025.

Return on Capital Employed (ROCE) of Resverlogix changed from 5.63 % to 5.86 %, representing a 4.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Resverlogix since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Resverlogix with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Resverlogix

All Key Metrics — Resverlogix